Cargando...
PEGylated IL-11 (BBT-059), a novel radiation countermeasure for hematopoietic acute radiation syndrome
Interleukin11 was developed to reduce chemotherapy-induced thrombocytopenia, however, its clinical use was limited by severe adverse effects in humans. PEGylated -IL-11 (BBT-059), developed by Bolder Biotechnology, Inc., exhibited a longer half-life in rodents and induced longer-lasting increases in...
Gardado en:
| Publicado en: | Health Phys |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5967654/ https://ncbi.nlm.nih.gov/pubmed/29787432 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/HP.0000000000000841 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|